C2N

C2N Diagnostics, established in 2007, is a biotechnology firm operating in the clinical diagnostics sector with a specific focus on neurodegenerative diseases. The company emerged as a spinoff from the Washington University School of Medicine in St. Louis, founded by Dr. David Holtzman and Dr. Randall Bateman, whose research has been foundational in the field of Alzheimer's diagnostics. Their scientific background and extensive work on blood-based biomarkers for Alzheimer's disease are central to the company's mission. C2N Diagnostics develops and commercializes advanced diagnostic tests for early detection and monitoring of neurological conditions.

The company's core business revolves around providing blood tests that identify specific protein biomarkers, such as amyloid and tau, which are indicators of Alzheimer's disease. This approach offers a less invasive and more accessible alternative to traditional diagnostic methods like PET scans and cerebrospinal fluid analysis. The primary clients for these diagnostic services include individuals experiencing cognitive symptoms, physicians, and pharmaceutical companies conducting clinical trials for Alzheimer's treatments. Revenue is generated from the sale of these diagnostic tests, including the PrecivityAD2 and PrecivityAD blood tests, which are processed in C2N's CLIA-certified laboratory.

C2N's flagship offering, the PrecivityAD2 blood test, analyzes blood plasma to determine the presence of amyloid plaques in the brain, a hallmark of Alzheimer's. The test provides a score that helps physicians assess the likelihood of Alzheimer's pathology, aiding in a more timely and accurate diagnosis. Another key product is the p-tau217 Ratio test, which measures a specific variant of the tau protein and has shown high accuracy in detecting both amyloid and tau pathologies, further enhancing diagnostic capabilities. These tests represent a significant step forward in making early diagnosis of Alzheimer's disease a routine part of clinical practice.

Keywords: neurodegenerative diagnostics, Alzheimer's disease, blood-based biomarkers, clinical diagnostics, mass spectrometry, p-tau217, amyloid beta, neurology, diagnostic tests, biotechnology